Commercial Printing

Amgen Inc. (AMGN) received a boost with the EU approval of its lead pipeline candidate, Prolia (denosumab). The European Commission granted approval for the use of Prolia in the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and the treatment of bone loss...

Dell Inc. (DELL) reported first quarter 2011 EPS of 30 cents, exceeding the Zacks Consensus Estimate of 26 cents. Revenue Revenue for the quarter was $14.9 billion, up 21.0% from $12.3 billion reported in the year-ago quarter and almost flat compared to $14.9 billion reported in the previous...

Stocks slide as Euro hits 4-year low on ongoing economic concerns Stocks are lower in early trading even as investors remain cautious about the health of Europe’s economy. Stocks are moving slightly lower Monday after the euro bounced off the four-year low it hit earlier in the day. Investors are...

Stocks are down on European economic concerns Stocks are falling in early trading on concerns about how austerity measures in Europe might slow the continent’s economy. Better-than-expected reports on U.S. retail sales and industrial production didn’t help stock prices. Investors are focusing on...

• Goldman Sachs (NYSE:GS) removed Merck (NYSE:MRK) from its Conviction Buy List, cutting its rating to "neutral," and lowering the price target from $46 to $42 • Time Warner (NYSE:TWX) reported better-than-expected first quarter earnings of 61 cents a share, ahead of Zacks estimates of 48 cents on...

For Immediate Release Chicago, IL – April 28, 2010 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: United...

  Recently, Merck (MRK) entered into a co-promotion agreement with Nycomed for the commercialization of Daxas (roflumilast) in Canada and certain European countries. The drug is meant to treat patients with chronic obstructive pulmonary disease (COPD). The two companies have also signed a...

Pfizer Inc.’s (PFE) Sutent faced yet another development setback when the company announced the discontinuation of a phase III study with the candidate for the treatment of liver cancer (advanced hepatocellular carcinoma).   Pfizer halted the trial based on a review conducted by an independent...

Recently, GlaxoSmithKline (GSK) and Denmark-based Genmab AS received a conditional marketing authorization for Arzerra (ofatumumab) from the European Commission. The drug, a monoclonal antibody, is indicated for patients with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone...

Recently, OSI Pharmaceuticals (OSIP) received approval from the US Food and Drug Administration (FDA) for its lead product, Tarceva (erlotinib) as a maintenance therapy for patients suffering from non-small-cell lung cancer (NSCLC), whose disease has not worsened after multiple rounds of...

Recently, Novartis (NVS) received approval both in the European Union (EU) and the US for Menveo, a quadrivalent conjugate vaccine for the prevention of meningococcal disease. The US Food and Drug Administration (FDA) approval is for the age group of 11−55 years.   In Europe, the vaccine has been...

Recently, a European advisory committee recommended the approval of Tarceva (erlotinib) as a maintenance therapy for patients suffering from lung cancer following multiple rounds of chemotherapy. Tarceva is the lead drug of OSI Pharmaceuticals Inc. (OSIP). Tarceva has been co-developed with...

Nexen Inc. (USA) (NYSE: NXY) and its partner reported today that they have made a significant discovery in the Eastern Gulf of Mexico at Appomattox, located in Mississippi Canyon blocks 391 and 392. Nexen increased 3.99% to $24.50 in the pre-market session. The 52-week trading range for NXY is $15....

GlaxoSmithKline Plc. (GSK) recently received good news in the form of European approval for its oral thrombopoetin agonist, Revolade (eltrombopag). The European Commission (EC) granted marketing approval to the product for the oral treatment of thrombocytopenia or reduced platelet count in adults...